Drugs / MDX-1379
last change Oct 2009 re-read 2 minutes ago

MDX-1379

Vaccine

Developed for
melanoma · metastatic neoplasm
Investigated by
Bristol-Myers Squibb

Trials 1 · a red edge is where a trial was stopped

20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT00094653 Sep 2004 → Aug 2009 melanoma, metastatic neoplasm Bristol-Myers Squibb Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as MDX-1379 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00094653
Modality Vaccine “MDX-1379 (gp100) Melanoma Peptide VaccineNCT00094653